Vorasidenib
Vorasidenib Phase 1
Servier · Phase n/r · Status n/r · Enrollment n/r
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Vorasidenib, non-enhancing glioma | recurrent non-enhancing IDH-mutant glioma (n = 22) | Phase 1 doses | Single arm | n/r | objective response rate: 18%, Phase 1median PFS: 36.8 months, Phase 1 |